This page is updated frequently with new Bowel-related patent applications.
| System and facilitating assessment of the bowel course and facilitation of transition point detection on cross-sectional radiologic digital images by elimination of air-fluid levels during image post-processing.|
Novel application of pre-existing flood-fill and thresholding algorithms to radiologic images for the purposes of facilitating and accelerating the task of visual radiologic evaluation of the gastrointestinal tract is presented. This invention facilitates evaluation, in a manner that is useful in the contexts of finding a bowel transition point in cases of suspected bowel obstruction, and for facilitating determination of prior unknown surgical bowel alteration (such as roux-en-y, billroth procedures).
| Antisense compositions and methods of making and using same|
The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against smad7. The pharmaceutical formulations can be used to treat crohn's disease, ulcerative colitis and chronic inflammatory bowel disease..
Nogra Pharma Limited
| Semen cassiae-containing tea bag and preparation method thereof|
The invention discloses a semen cassiae-containing tea bag and preparation method thereof. The semen cassiae-containing tea bag comprises semen cassiae, chrysanthemum, lotus leaf and folium mori.
Jiangsu Daocheng Biotechnology Co., Ltd
| Methods for retreating irritable bowel syndrome (ibs)|
The present invention provides new methods and kits for the retreatment of ibs.. .
Salix Pharmaceuticals, Inc.
| Apparatus and methods of inducing weight loss using blood flow control|
Methods and apparatus for inducing weight loss using blood flow control are described herein. The apparatus and methods operate by controlling blood flow to the stomach and/or small bowel..
Mayo Foundation For Medical Education And Research
|Urea compounds and their use as enzyme inhibitors|
Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..
|Human antibodies to human tnf-like ligand 1a (tl1a)|
A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human tnf-like ligand 1a (htl1a) is provided. The human anti-htl1a antibodies are useful in treating diseases or disorders associated with tl1a, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation..
Regeneron Pharmaceuticals, Inc.
|Inhibition of gliadin peptides|
Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation
|Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions|
Disclosed is a method of treating small intestinal bacterial overgrowth (sibo) or a sibo-caused condition in a human subject. Sibo-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and crohn's disease.
Cedars-sinai Medical Center
|Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof|
A pharmaceutical composition or formulation adapted for oral administration in tablet, coated tablet, capsule or reconstitutable powder form for the prevention or treatment of intestinal disorders such irritable bowel syndrome, also known as irritable colon syndrome, based on an intestinal motility modifier, an agent that prevents gas retention, of digestive enzymes, a binding agent, a diluting agent, an absorbent agent, a lubricant, aglidant, and an disintegrating agent or suspending agent, effective in the normalization of intestinal disorders, to achieve an analgesic activity, to achieve an anti-spasmic activity and to reduce the symptoms associated with intestinal gas such as distention, abdominal pain and flatulence.. .
Posi Visionary Solutions, Llp
Method for supporting gut health
Calcium pyruvate and derivatives or formulations thereof can be employed for supporting gut health and lessen inflammations, for example in chronic inflammatory diseases of the digestive tract, and irritable bowel syndrome. Therefore, the invention relates to the use of calcium pyruvate preparations for treating inflammatory diseases, especially of the digestive tract of humans and mammalian animals, pets and livestock.
Antibodies that specifically bind to tl1a
Recombinantly expressed variant antibodies that have enhanced affinity for tl1a and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between tl1a and the death receptor 3 (dr3).
Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions thereof, and methods of use
Cysteine, n-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions comprising the cysteine, n-acetylcysteine, and penicillamine related compounds, and methods of using cysteine, n-acetylcysteine, and penicillamine related compounds and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including paracetamol overdose, non-alcoholic steatohepatitis, wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, parkinson's disease, and huntington's disease.. .
Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (ibd)
A nutritional composition promotes musculoskeletal health in patients with inflammatory bowel disease. The nutritional composition contains casein protein, vitamin d, alpha-linolenic acid, and vitamin k in a ratio of vitamin k1:vitamin k2 between 3:1 to 1:3 and the vitamin k providing between 3.5-20 μg/100 cal of the nutritional composition.
Female urinary barrier system
A female urinary barrier system product that includes an exterior vaginal attachment pad for providing a female-user with means to prevent the spread of infectious diseases into their vaginal opening and urinary tract. The product provides a female-user a hand depressible attachment pad useful for enclosing/covering the vagina prior to a bowel movement or just prior to wiping.
Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by administering an anti-cgrp antagonist antibody.. .
Labrys Biologics, Inc.
Gene expression based biomarker system for irritable bowel syndrome (ibs) diagnosis
We have identified a suite of genes in a limited number of human colonic tissue samples with expression patterns that correlate with whether an individual is experiencing symptoms of irritable bowel syndrome (ibs) (fig. 2).
Arizona Board Of Regents On Behalf Of Arizona State University
Pharmaceutical compositions comprising glitazones and nrf2 activators
The invention relates to pharmaceutical compositions comprising ppar agonists and nrf2 activators and methods of using combinations of ppar agonists and nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.. .
Methods for diagnosis and prognosis of inflammatory bowel disease using cytokine profiles
The present invention relates to the field of inflammatory bowel disease. More specifically, the present invention relates to the use of cytokines to detect, diagnose, and assess inflammatory bowel disease.
Oklahoma Medical Research Foundation
Biomarker for diagnosis of irritable bowel syndrome
To provide a biomarker which is a metabolite included in a biological sample, and which can be collected in a noninvasive method and detected in a convenient analysis method, and which varies according to progression of pathological conditions of irritable bowel syndrome (ibs). Furthermore, such biomarkers are useful for determination of the presence or absence of morbidity of ibs, determination of severity of ibs, determination of types of ibs, determination of necessity of treatment of ibs, and confirmation of drug efficacy of an ibs therapeutic agent..
Ono Pharmaceutical Co., Ltd.
Inflammatory Bowel Disease
Irritable Bowel Syndrome
Follow us on Twitter
This listing is a sample listing of patent applications related to Bowel for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bowel with additional patents listed. Browse our RSS directory or Search for other possible listings.